ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR53

Effects of Daprodustat on Hemoglobin and Quality of Life in Patients with CKD: Results of the ASCEND-NHQ Randomized, Double-Blind, Placebo-Controlled Trial

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Johansen, Kirsten L., Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, United States
  • Cobitz, Alexander Ralph, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Lopes, Renato D., Duke Clinical Research Institute, Duke Health, Durham, North Carolina, United States
  • Singh, Ajay K., Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States
  • Obrador, Gregorio T., Universidad Panamericana School of Medicine, Mexico City, Mexico
  • Cizman, Borut, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Macdougall, Iain C., King’s College Hospital, London, United Kingdom
  • Okoro, Tony, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Sprys, Michael, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Jha, Vivekanand, George Institute for Global Health, New Delhi, India
  • Jolly, Shivinder Singh, Clinical Research Solutions Inc, Waterloo, Ontario, Canada
  • Israni, Rubeen K., GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Wheeler, David C., Department of Renal Medicine, University College London, London, United Kingdom
Background

Daprodustat (dapro) is a hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treating anemia of chronic kidney disease (CKD). In a Phase 3 trial in non-dialysis dependent (ND) CKD patients, we evaluated the effect of dapro vs placebo (PBO) on hemoglobin (Hb) and the SF-36 quality of life Vitality score (fatigue) over 28 weeks.

Methods

Adults with CKD stage 3–5, Hb 8.5–10.0 g/dL, transferrin saturation ≥15%, ferritin ≥50 ng/ml without recent rhEPO use were randomized 1:1 to dapro or PBO to maintain Hb 11–12 g/dL (NCT03409107). Primary endpoint was mean change in Hb between baseline (BL) and the evaluation period (mean over Wk 24–28). Principal secondary endpoints were 1) proportion with ≥1 g/dL increase in Hb, 2) mean change in SF-36 Vitality (fatigue) between BL and Wk 28. SF-36 Vitality responder (≥6 point increase) and blood pressure (BP) elevations were secondary endpoints. Superiority for all endpoints was tested (1-sided α=0.025).

Results

614 ND-CKD patients were randomized. BL demographic characteristics were balanced; Hb was similar (9.73 g/dL dapro, 9.71 g/dL PBO). The adjusted mean difference (AMD) in change in Hb was 1.40 g/dL (95% CI 1.23, 1.56; P<0.001). A greater proportion on dapro had a ≥1 g/dL increase in Hb from BL (77% vs 18%; P<0.001). Adjusted mean (SE) SF-36 Vitality score increased by 7.3 (1.1) points (dapro) vs 1.9 (1.2) points (PBO); AMD at Wk 28 was 5.4 (95% CI 2.2, 8.6; P<0.001, Figure). 58% on dapro vs 40% on PBO were SF-36 Vitality responders (difference 13%; 95% CI 4%, 22%). While more BP elevations occurred in dapro vs PBO (32% vs 26%, p=0.07), dapro's overall effect on BP was similar to PBO. Rates of adverse events were similar (dapro 69% vs PBO 71%).

Conclusion

In patients with ND-CKD, dapro effectively increased Hb, significantly improved the vitality score (fatigue) and was well tolerated.

Funding

  • Commercial Support